 AUSTIN, Texas--BUSINESS WIRE--Anebulo Pharmaceuticals, Inc. Nasdaq: ANEB, a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication ACI and substance abuse disorder the Company or Anebulo, anticipates releasing topline data from Part A of its ongoing Phase 2 study of ANEB-001 on July 5th. The results of the study, conducted in sixty healthy subjects challenged with delta-9-tetrahydrocannabinol, better known as THC, 